Amanda Saunders, DO

Deciphera Pharmaceuticals, LLC
Waltham, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST